Tissue-Specific Wnt Signal Enhancing Molecules
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for modulating Wnt signaling lack tissue-specificity, leading to unintended effects due to the broad expression of Wnt ligands and receptors across various tissues, necessitating the development of strategies to enhance Wnt activity in a tissue-specific manner for therapeutic applications.
Innovation Solution
The development of tissue-specific Wnt signal enhancing molecules comprising a domain that binds to E3 ubiquitin ligases ZNRF3 or RNF43 and a domain specific to a tissue-specific cell surface receptor, which mediate the internalization or sequestration of these ligases, thereby stabilizing Wnt receptors and enhancing Wnt signaling in targeted tissues.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If R-spondins are used to enhance Wnt signaling, then Wnt signal amplification is achieved, but tissue-specificity is lost due to broad expression of LGR4-6 and ZNRF3/RNF43
Solution Approach 1:
The patent modifies R-spondin molecules by replacing their native LGR4-6 binding domains with tissue-specific binding domains, creating heterogeneity in binding specificity across different R-spondin variants. This allows each R-spondin molecule to target specific tissues expressing particular cell surface receptors while maintaining the core Wnt signal amplification mechanism through ZNRF3/RNF43 binding.
Solution Approach 2:
The patent introduces tissue-specific cell surface receptors as intermediary targets. Instead of R-spondins directly binding LGR4-6 in a non-specific manner, the modified R-spondins first bind to tissue-specific receptors, which then mediate the delivery and activation of Wnt signaling in a controlled, tissue-specific manner.
2Reliability
If Wnt signaling is enhanced systemically, then therapeutic effects are achieved, but off-target effects occur due to broad receptor expression
Solution Approach 1:
By engineering R-spondin molecules with tissue-specific binding domains, the patent ensures that Wnt signal enhancement occurs only in tissues expressing the corresponding cell surface receptors. This localized action eliminates off-target effects in tissues that do not express the target receptors, while maintaining therapeutic efficacy in the intended tissue.
3Adaptability or versatility
If multiple Wnt ligands and receptors are targeted, then comprehensive Wnt pathway modulation is achieved, but selectivity is reduced
Solution Approach 1:
The patent segments the Wnt modulation approach by creating distinct R-spondin variants, each tailored to bind specific tissue-specific receptors. This segmentation allows selective targeting of different Wnt signaling pathways in different tissues, maintaining comprehensive pathway modulation capability while achieving high selectivity through receptor-specific binding.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach allows for targeted enhancement of Wnt signaling in specific tissues, potentially treating and preventing diseases associated with reduced Wnt activity by increasing Wnt signaling in a tissue-specific and controlled manner, minimizing off-target effects.
Implementation Method 1
the molecule internalizes or sequesters ZNRF3/RNF43 in the target tissue
Implementation Method 2
a second domain that specifically binds a tissue-specific cell surface molecule
Data Source
AI summary
The present disclosure provides tissue-specific Wnt signal enhancing molecules, and related methods of using these molecules to increase Wnt signaling in targeted tissues.